HUP0203470A2 - Eljárás kimerültség, fejsérülés és szélütés kezelésére - Google Patents
Eljárás kimerültség, fejsérülés és szélütés kezeléséreInfo
- Publication number
- HUP0203470A2 HUP0203470A2 HU0203470A HUP0203470A HUP0203470A2 HU P0203470 A2 HUP0203470 A2 HU P0203470A2 HU 0203470 A HU0203470 A HU 0203470A HU P0203470 A HUP0203470 A HU P0203470A HU P0203470 A2 HUP0203470 A2 HU P0203470A2
- Authority
- HU
- Hungary
- Prior art keywords
- inhibitor
- treatment
- stroke
- reuptake
- fatigue
- Prior art date
Links
- 206010019196 Head injury Diseases 0.000 title 1
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 229960002748 norepinephrine Drugs 0.000 abstract 2
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 abstract 2
- 230000000966 norepinephrine reuptake Effects 0.000 abstract 2
- GJJFMKBJSRMPLA-HIFRSBDPSA-N (1R,2S)-2-(aminomethyl)-N,N-diethyl-1-phenyl-1-cyclopropanecarboxamide Chemical compound C=1C=CC=CC=1[C@@]1(C(=O)N(CC)CC)C[C@@H]1CN GJJFMKBJSRMPLA-HIFRSBDPSA-N 0.000 abstract 1
- ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 abstract 1
- 208000000532 Chronic Brain Injury Diseases 0.000 abstract 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 abstract 1
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 abstract 1
- 208000001640 Fibromyalgia Diseases 0.000 abstract 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 abstract 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 229940124639 Selective inhibitor Drugs 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 210000004556 brain Anatomy 0.000 abstract 1
- 230000000994 depressogenic effect Effects 0.000 abstract 1
- 229960003914 desipramine Drugs 0.000 abstract 1
- 230000002825 dopamine reuptake Effects 0.000 abstract 1
- 239000002552 dosage form Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229960002866 duloxetine Drugs 0.000 abstract 1
- 206010016256 fatigue Diseases 0.000 abstract 1
- 208000002551 irritable bowel syndrome Diseases 0.000 abstract 1
- 229960002813 lofepramine Drugs 0.000 abstract 1
- SAPNXPWPAUFAJU-UHFFFAOYSA-N lofepramine Chemical compound C12=CC=CC=C2CCC2=CC=CC=C2N1CCCN(C)CC(=O)C1=CC=C(Cl)C=C1 SAPNXPWPAUFAJU-UHFFFAOYSA-N 0.000 abstract 1
- 229960000600 milnacipran Drugs 0.000 abstract 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 abstract 1
- 230000000926 neurological effect Effects 0.000 abstract 1
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 abstract 1
- 229940126569 noradrenaline reuptake inhibitor Drugs 0.000 abstract 1
- 230000002474 noradrenergic effect Effects 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 abstract 1
- 229960003770 reboxetine Drugs 0.000 abstract 1
- CBQGYUDMJHNJBX-RTBURBONSA-N reboxetine Chemical compound CCOC1=CC=CC=C1O[C@H](C=1C=CC=CC=1)[C@@H]1OCCNC1 CBQGYUDMJHNJBX-RTBURBONSA-N 0.000 abstract 1
- 230000000697 serotonin reuptake Effects 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 abstract 1
- 229960004688 venlafaxine Drugs 0.000 abstract 1
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Finger-Pressure Massage (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A találmány tárgya eljárás neurológiai eredetű rendellenességekkezelésére, továbbá gyógyszerkészítmények ebben az eljárásban valófelhasználásra. Ezek az állapotok és rendellenességek magukbanfoglalják a kimerültséget, amely fájdalom szindrómáival társul, agyengeséget és depressziós viselkedést, amely krónikus kimerültségiszindrómával társul, agysérülést és szélütést, stresszt, fibromialgiátés ingerelhető bél szindrómát. A kezelés magában foglalja egy ilyenigény esetén noradrenalin újrafelvétel szelektív inhibitoránakbeadását e kombinálva fenil-alaninnal vagy tirozinnal azonos dózisformában vagy azonos csomagban. A noradrenerg gyógyszer lehetlofepramin, dezipramin vagy reboxetin. A szelektív inhibitor lehetmind a noradrenalin, mind a szerotonin újrafelvétel kombináltinhibitora, mint a venlafaxin, duloxetin vagy milnacipran, vagy mind anoradrenalin, mind a dopamin újrafelvétel inhibitora, mint abupropion. Ó
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9924172A GB2355191A (en) | 1999-10-12 | 1999-10-12 | Combination formulations for fatigue, head injury and strokes |
PCT/GB2000/003926 WO2001026623A2 (en) | 1999-10-12 | 2000-10-12 | Treatment of fatigue, head injury and stroke |
Publications (2)
Publication Number | Publication Date |
---|---|
HUP0203470A2 true HUP0203470A2 (hu) | 2003-02-28 |
HUP0203470A3 HUP0203470A3 (en) | 2005-10-28 |
Family
ID=10862624
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0203470A HUP0203470A3 (en) | 1999-10-12 | 2000-10-12 | Treatment of fatigue, head injury and stroke |
Country Status (15)
Country | Link |
---|---|
US (1) | US6441038B1 (hu) |
EP (1) | EP1220689B1 (hu) |
AU (1) | AU782656B2 (hu) |
CA (1) | CA2388377C (hu) |
CZ (1) | CZ20021197A3 (hu) |
DE (1) | DE60042598D1 (hu) |
GB (1) | GB2355191A (hu) |
HR (1) | HRP20020309A2 (hu) |
HU (1) | HUP0203470A3 (hu) |
MX (1) | MXPA02003724A (hu) |
NO (1) | NO20021716L (hu) |
NZ (1) | NZ518306A (hu) |
PL (1) | PL354975A1 (hu) |
SK (1) | SK4672002A3 (hu) |
WO (1) | WO2001026623A2 (hu) |
Families Citing this family (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2246485T3 (es) | 1999-07-01 | 2006-02-16 | PHARMACIA & UPJOHN COMPANY LLC | (s,s)-reboxetina para tratar la incontinencia. |
US20040048874A1 (en) * | 2001-05-22 | 2004-03-11 | Bardsley Hazel Judith | New therapeutic use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine |
GB0216027D0 (en) | 2002-07-10 | 2002-08-21 | Arachnova Therapeutics Ltd | New therapeutic use |
US6602911B2 (en) | 2001-11-05 | 2003-08-05 | Cypress Bioscience, Inc. | Methods of treating fibromyalgia |
US6635675B2 (en) | 2001-11-05 | 2003-10-21 | Cypress Bioscience, Inc. | Method of treating chronic fatigue syndrome |
CA2475763A1 (en) * | 2002-02-12 | 2003-08-21 | Cypress Bioscience, Inc. | Methods of treating attention deficit/hyperactivity disorder (adhd) |
US20030176773A1 (en) * | 2002-03-12 | 2003-09-18 | Gendreau Roger Michael | Methods of assessing the level of a subjective symptom |
ES2399880T3 (es) * | 2002-03-15 | 2013-04-04 | Cypress Bioscience, Inc. | Milnaciprán para el tratamiento del síndrome del intestino irritable |
US20030232805A1 (en) * | 2002-04-24 | 2003-12-18 | Cypress Bioscience, Inc. | Prevention and treatment of functional somatic disorders, including stress-related disorders |
US7109198B2 (en) * | 2002-05-17 | 2006-09-19 | Duke University | Method for treating obesity |
TW200402289A (en) * | 2002-05-17 | 2004-02-16 | Wyeth Corp | Methods of treating gastrointestinary and genitourinary pain disorders |
US20050215552A1 (en) * | 2002-05-17 | 2005-09-29 | Gadde Kishore M | Method for treating obesity |
US20070129438A1 (en) * | 2002-07-11 | 2007-06-07 | Yuuichi Murayama | Method for suppressing proliferation of abnormal prion protein |
CA2500662A1 (en) * | 2002-10-03 | 2004-04-15 | Cypress Bioscience, Inc. | Dosage escalation and divided daily dose of anti-depressants to treat neurological disorders |
US7704527B2 (en) * | 2002-10-25 | 2010-04-27 | Collegium Pharmaceutical, Inc. | Modified release compositions of milnacipran |
JP2006508978A (ja) * | 2002-11-19 | 2006-03-16 | イーライ・リリー・アンド・カンパニー | デュロキセチンを用いる胃腸障害の処置 |
NZ541009A (en) * | 2003-01-13 | 2007-09-28 | Dynogen Pharmaceuticals Inc | Method of treating nausea, vomiting, retching or any combination thereof |
EP1558081A4 (en) * | 2003-01-13 | 2006-06-14 | Dynogen Pharmaceuticals Inc | METHOD OF TREATING FUNCTIONAL INTESTINAL DISORDERS |
FR2851163B1 (fr) | 2003-02-14 | 2007-04-27 | Utilisation de l'enantiomere dextrogyre du milnacipran pour la preparation d'un medicament | |
EP1908461B9 (fr) | 2003-02-14 | 2011-08-31 | Pierre Fabre Medicament | Utilisation de l'énantiomère (1S, 2R) du milnacipran pour la préparation d'un médicament |
AU2004227945B2 (en) | 2003-04-04 | 2006-10-26 | Dynogen Pharmaceuticals, Inc. | Method of treating lower urinary tract disorders |
CA2522708C (en) | 2003-04-29 | 2013-05-28 | Orexigen Therapeutics, Inc. | Compositions for affecting weight loss |
WO2004105690A2 (en) * | 2003-05-23 | 2004-12-09 | Cypress Bioscience, Inc. | Treatment of chronic pain associated with drug or radiation therapy |
GB0313630D0 (en) * | 2003-06-12 | 2003-07-16 | Wwk Trust The | Compositions for the enhanced treatment of depression |
US7442372B2 (en) | 2003-08-29 | 2008-10-28 | Biomarin Pharmaceutical Inc. | Delivery of therapeutic compounds to the brain and other tissues |
AU2004291149C1 (en) | 2003-11-17 | 2021-01-21 | Biomarin Pharmaceutical Inc. | Methods and Compositions for the Treatment of Metabolic Disorders |
US20060160750A1 (en) * | 2004-01-13 | 2006-07-20 | Krishnan K R R | Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss |
KR20060128995A (ko) | 2004-01-13 | 2006-12-14 | 듀크 유니버시티 | 체중감량에 영향을 미치는 항경련제와 항정신병 약물의조성물 |
US7713959B2 (en) * | 2004-01-13 | 2010-05-11 | Duke University | Compositions of an anticonvulsant and mirtazapine to prevent weight gain |
US20060100205A1 (en) * | 2004-04-21 | 2006-05-11 | Eckard Weber | Compositions for affecting weight loss |
RU2007103313A (ru) * | 2004-08-03 | 2008-09-10 | ОРЕКСИДЖЕН ТЕРАПЬЮТИКС, ИНК. (Канада/США) (US) | Комбинация бупропина и другого состава для эффективной потери веса |
EP1793829A1 (en) * | 2004-10-01 | 2007-06-13 | Neurocure Ltd. | Use of pharmaceutical compositions of lofepramine for the treatment of adhd, cfs, fm and depression |
US8003126B2 (en) | 2004-11-17 | 2011-08-23 | Biomarin Pharmaceutical Inc. | Stable tablet formulation |
CA2588994A1 (en) * | 2004-12-08 | 2006-06-15 | Biomarin Pharmaceutical Inc. | Methods and compositions for the treatment of pulmonary hypertension of the newborn |
US20060293309A1 (en) * | 2005-03-28 | 2006-12-28 | Dynogen Pharmaceuticals, Inc. | Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors |
US7994220B2 (en) * | 2005-09-28 | 2011-08-09 | Cypress Bioscience, Inc. | Milnacipran for the long-term treatment of fibromyalgia syndrome |
CN101370488B (zh) | 2005-11-22 | 2012-07-18 | 奥雷西根治疗公司 | 增加胰岛素敏感性的组合物 |
WO2007089318A2 (en) * | 2005-11-23 | 2007-08-09 | Orexigen Therapeutics, Inc. | Compositions and methods for reducing food cravings |
JP2009517393A (ja) * | 2005-11-28 | 2009-04-30 | オレキシジェン・セラピューティクス・インコーポレーテッド | 不安症の治療方法 |
EP1965803A1 (en) * | 2005-12-05 | 2008-09-10 | Biomarin Pharmaceutical Inc. | Methods and compositions for the treatment of disease |
WO2007088473A2 (en) * | 2006-02-03 | 2007-08-09 | Neurocure Ltd | Treatment and prevention of depression with pain, depression secondary to pain, and of neuropathic pain |
US8916195B2 (en) | 2006-06-05 | 2014-12-23 | Orexigen Therapeutics, Inc. | Sustained release formulation of naltrexone |
CN101534819A (zh) | 2006-09-12 | 2009-09-16 | 阿得罗公司 | 含氮的螺环化合物用于增强认知功能的应用 |
WO2008042773A2 (en) * | 2006-09-29 | 2008-04-10 | Pdxrx, Inc. | Unitary pharmaceutical composition, method, and kit for the treatment or prevention of metabolic or endocrine disorders |
TWI504419B (zh) | 2006-11-09 | 2015-10-21 | Orexigen Therapeutics Inc | 層狀醫藥調配物 |
JP2010508997A (ja) | 2006-11-09 | 2010-03-25 | オレキシジェン・セラピューティクス・インコーポレーテッド | 減量薬を投与するための方法 |
WO2008089148A1 (en) * | 2007-01-12 | 2008-07-24 | Biomarin Pharmaceutical Inc. | Method of treating a metabolic or neuropsychiatry disorder with a bh4 derivative prodrug |
PT2545939T (pt) | 2007-04-11 | 2021-02-17 | Biomarin Pharm Inc | Métodos de administração de tetra-hidrobiopterina, composições associadas, e métodos de medição |
CA3056205C (en) | 2007-05-01 | 2023-09-26 | Concert Pharmaceuticals Inc. | Morphinan compounds |
WO2009158114A1 (en) | 2008-05-30 | 2009-12-30 | Orexigen Therapeutics, Inc. | Methods for treating visceral fat conditions |
US20100069389A1 (en) * | 2008-09-06 | 2010-03-18 | Bionevia Pharmaceuticals, Inc. | Novel forms of reboxetine |
EP2397158B1 (en) * | 2008-10-30 | 2016-04-13 | Concert Pharmaceuticals, Inc. | Combination of morphinan compounds and antidepressant for the treatment of pseudobulbar affect |
EP2496079A4 (en) | 2009-11-06 | 2014-05-14 | Pierre Fabre Médicament Sas | NOVEL (1S, 2R) -2- (AMINOMETHYL) -N, N-DIETHYL-1-PHENYLCYCLOPROPANECARBOXAMIDE CRYSTALLINE FORMS |
RU2616496C2 (ru) | 2010-01-11 | 2017-04-17 | Ориксиджен Терапьютикс, Инк. | Способы проведения терапии потери веса у пациентов с доминирующей депрессией (варианты) |
US20120289744A1 (en) | 2010-11-03 | 2012-11-15 | Arch Pharmalabs Limited | Process for preparing optically pure milnacipran and its pharmaceutically acceptable salts |
WO2012178014A1 (en) * | 2011-06-24 | 2012-12-27 | K-Pax Pharmaceuticals, Inc. | Compositions and methods for treatment of chronic fatigue |
US9216178B2 (en) | 2011-11-02 | 2015-12-22 | Biomarin Pharmaceutical Inc. | Dry blend formulation of tetrahydrobiopterin |
RU2493839C1 (ru) * | 2012-02-28 | 2013-09-27 | Федеральное бюджетное учреждение науки "Московский научно-исследовательский институт эпидемиологии и микробиологии им. Г.Н. Габричевского" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека | Способ лечения синдрома хронической усталости |
DK2858640T3 (da) | 2012-06-06 | 2020-06-29 | Nalpropion Pharmaceuticals Llc | Sammensætning til anvendelse i en fremgangsmåde til behandling af overvægt og fedme hos patienter med høj cardiovaskulær risiko |
US20190381056A1 (en) | 2018-06-17 | 2019-12-19 | Axsome Therapeutics, Inc. | Compositions for delivery of reboxetine |
US20200147093A1 (en) | 2018-10-15 | 2020-05-14 | Axsome Therapeutics, Inc. | Use of esreboxetine to treat nervous system disorders such as fibromyalgia |
US11020402B2 (en) | 2018-10-15 | 2021-06-01 | Axsome Therapeutics, Inc. | Use of reboxetine to treat narcolepsy |
US20200237875A1 (en) * | 2019-01-30 | 2020-07-30 | Synlev Pharmaceuticals Corporation | Formulations and methods for treatment of fibromyalgia and related myofascial pain disorders |
US11977085B1 (en) | 2023-09-05 | 2024-05-07 | Elan Ehrlich | Date rape drug detection device and method of using same |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4431670A (en) * | 1980-12-19 | 1984-02-14 | Bernardo Heller | D-Phenylalanine treatment |
US4843071A (en) * | 1986-12-05 | 1989-06-27 | Serotonin Industries Of Charleston | Method and composition for treating obesity, drug abuse, and narcolepsy |
HU225493B1 (en) * | 1994-10-05 | 2007-01-29 | Amarin Neuroscience Ltd | Use of antidepressants, mao inhibitors and serotonine reuptake inhibitors for the treatment of multiple sclerosis (ms) and other demyelinating conditions |
GB2297868B (en) | 1995-02-07 | 1999-04-28 | Nokia Mobile Phones Ltd | A shielding device |
JP3128609B2 (ja) | 1996-02-01 | 2001-01-29 | 株式会社小糸製作所 | 車輌用灯具の照射方向制御装置 |
AU3451797A (en) * | 1996-07-05 | 1998-02-02 | Andrew Peter Worsley | Compositions for the treatment of peripheral neuropathies containing antidepressants and/or monoamine oxidase inhibitors and/or vitamin b12 and/or precursors or inducers of a neurotransmitter |
US5765240A (en) * | 1996-07-31 | 1998-06-16 | L&P Property Management Co. | Spring bedding product collapsible in the transverse direction, and method of making it |
GB9617990D0 (en) * | 1996-08-29 | 1996-10-09 | Scotia Holdings Plc | Treatment of pain |
GB9618341D0 (en) * | 1996-09-03 | 1996-10-16 | Scotia Holdings Plc | Method of treatment |
-
1999
- 1999-10-12 GB GB9924172A patent/GB2355191A/en not_active Withdrawn
-
2000
- 2000-10-12 DE DE60042598T patent/DE60042598D1/de not_active Expired - Lifetime
- 2000-10-12 HU HU0203470A patent/HUP0203470A3/hu unknown
- 2000-10-12 PL PL00354975A patent/PL354975A1/xx not_active Application Discontinuation
- 2000-10-12 SK SK467-2002A patent/SK4672002A3/sk unknown
- 2000-10-12 AU AU79328/00A patent/AU782656B2/en not_active Ceased
- 2000-10-12 CA CA2388377A patent/CA2388377C/en not_active Expired - Fee Related
- 2000-10-12 CZ CZ20021197A patent/CZ20021197A3/cs unknown
- 2000-10-12 EP EP00969670A patent/EP1220689B1/en not_active Expired - Lifetime
- 2000-10-12 MX MXPA02003724A patent/MXPA02003724A/es not_active Application Discontinuation
- 2000-10-12 WO PCT/GB2000/003926 patent/WO2001026623A2/en active IP Right Grant
- 2000-10-12 NZ NZ518306A patent/NZ518306A/en not_active IP Right Cessation
- 2000-10-12 US US09/686,629 patent/US6441038B1/en not_active Expired - Fee Related
-
2002
- 2002-04-10 HR HR20020309A patent/HRP20020309A2/hr not_active Application Discontinuation
- 2002-04-11 NO NO20021716A patent/NO20021716L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
GB9924172D0 (en) | 1999-12-15 |
DE60042598D1 (de) | 2009-09-03 |
MXPA02003724A (es) | 2003-10-14 |
HRP20020309A2 (en) | 2004-02-29 |
CZ20021197A3 (cs) | 2002-09-11 |
EP1220689A2 (en) | 2002-07-10 |
EP1220689B1 (en) | 2009-07-22 |
GB2355191A (en) | 2001-04-18 |
AU7932800A (en) | 2001-04-23 |
CA2388377A1 (en) | 2001-04-19 |
NZ518306A (en) | 2004-04-30 |
SK4672002A3 (en) | 2002-09-10 |
WO2001026623A3 (en) | 2001-06-21 |
NO20021716L (no) | 2002-06-10 |
PL354975A1 (en) | 2004-03-22 |
HUP0203470A3 (en) | 2005-10-28 |
NO20021716D0 (no) | 2002-04-11 |
WO2001026623A2 (en) | 2001-04-19 |
CA2388377C (en) | 2011-02-01 |
US6441038B1 (en) | 2002-08-27 |
AU782656B2 (en) | 2005-08-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0203470A2 (hu) | Eljárás kimerültség, fejsérülés és szélütés kezelésére | |
WO2001062341A3 (en) | Combination product for the treatment of obesity | |
Baron et al. | Tolerability, safety, and quality of life with tapentadol prolonged release (PR) compared with oxycodone/naloxone PR in patients with severe chronic low back pain with a neuropathic component: a randomized, controlled, open‐label, phase 3b/4 trial | |
WO2004047830A3 (de) | Pharmazeutische zusammensetzung aus einem beta-3-adrenozeptor-agonisten und einem serotonin- und/oder norepinephrin-reuptake-inhibitor deren verwendung zur behandlung von blasenfunktionsstörungen | |
Pergolizzi et al. | The pharmacological management of dental pain | |
EE200100441A (et) | Monoamiinide taasomastamise inhibiitorid kesknärvisüsteemi haiguste raviks | |
ATE552856T1 (de) | Selektive norepinephrin-serotonin- wiederaufnahmehemmer zur behandlung des fibromyalgie-syndroms, des chronischen müdigkeitssyndroms und von schmerzen | |
WO2004010932A3 (en) | Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions | |
MY152919A (en) | Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders | |
WO2000032178A3 (en) | Use of siburamine for the treatment of disorders of the central nervous system secondary to organic impairments | |
ZA200509542B (en) | Combination of an NDMA receptor antagonist and a selective serotonin reuptake inhibitor for the treatment of depression and other mood disorders | |
AR026610A1 (es) | Un derivado pirrolidinacetamida solo o en combinacion para tratamiento de desordenes del sistema nervioso central | |
DK0429189T3 (da) | Anvendelse af sertralin til fremstilling af et lægemiddel til behandling af obsessiv-kompulsive sygdomme | |
HUP0303163A2 (hu) | Tramadolalapú gyógyszerkészítmény | |
HUP9801227A2 (hu) | Monoamin-oxidáz B inhibitorokból álló gyógyászati készítmények és alkalmazásuk | |
BR0210650A (pt) | Tablete, e, uso do mesmo | |
WO2004056335A3 (es) | Dispositivo de liberación que contiene venlafaxina y memantina | |
MXPA05012358A (es) | Combinacion farmaceutica que comprende modafinilo y otra droga. | |
EA200600603A1 (ru) | Оральная система доставки лекарственного препарата | |
BRPI0607684A2 (pt) | composição farmacêutica, método para prevenir ou tratar distúrbios de depressão ou ansiedade, e, uso de (s)-n-[2-(1,6,7,8-tetraidro-2h-indeno[5,4-b]furan-8-il)-eti l]-propionamida | |
EP1254668A3 (en) | Combination of a serotonin reuptake inhibitor and a GABA-A alpha 2/3 agonist for use in anxiety and depression | |
HUP0204050A2 (hu) | Mirtazapint és gepiront tartalmazó hatóanyagkombináció depresszió és rokon rendellenességek kezelésére | |
HUP0402619A2 (hu) | Norepinefrin re-uptake inhibitorok alkalmazása a megértési nehézségek kezelésére használható gyógyszer előállítására | |
BG108452A (en) | Tablet comprising cetirizine and pseudoephedrine | |
HUP0302436A2 (hu) | Antidepresszáns gyógyszerek által kiváltott szexuális rendellenességek kezelése apomorfinnal |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD9A | Lapse of provisional protection due to non-payment of fees |